Our Technology
We leverage MicroRNA (MiRNA) and epigenetics to develop proprietary drug screening platforms for cannabinoid-based treatments of neurological diseases, supported by Artificial Intelligence.
3D Brain Cell Technology
At CanniOasis, we’ve pioneered a unique technology to create 3D brain cell structures from stem cells, specifically designed to replicate midbrain cells—an area affected by Parkinson’s Disease (PD). Traditional lab methods rely on flat, 2D cell cultures, but our 3D approach enables cells to grow in a way that closely mimics their natural environment in the brain. This advancement allows us to study more accurate cellular behaviors and interactions, laying the groundwork for better neurological insights.
Human Midbrain-Like Organoids (hMLOs)
Our human midbrain-like organoids (hMLOs), developed in collaboration with A*Star and National University of Singapore, display neuromelanin granules and key characteristics similar to human midbrain tissue. These organoids incorporate midbrain-specific neurons (A9-like neurons) that express crucial markers (TH, DAT, and GIRK2), making them highly representative of real midbrain tissue. RNA-seq analysis from human prenatal midbrain samples shows that hMLOs better capture prenatal midbrain traits than traditional 2D neurons, underscoring their potential as valuable tools for studying midbrain functions and associated diseases.
Neuromelanin Production and Its Implications
One of our most remarkable discoveries is that our 3D hMLOs produce neuromelanin (NM)-like granules, unlike neurons grown in 2D or mouse-based organoids. NM is a dark pigment found in brain areas affected by PD, though its role remains a topic of debate—some research suggests a protective function, while others link it to inflammation and toxicity. Typically only accessible through post-mortem samples, NM is challenging to study. Our hMLOs provide a sustainable in-lab source of NM, allowing us to investigate its role in PD. These findings open new avenues for studying PD progression, potentially advancing personalized treatments and innovative therapies.
Accelerating cannabinoid drug development with enhanced efficiency and affordability
Our Approach - Cannabinoids
CanniOasis utilizes advanced drug delivery formulations to maximize drug effectiveness, targeting specific tissues with precision. By interacting with MiRNA and epigenetic proteins, cannabinoid treatments have shown promising effects on vital neurological pathways, as supported by extensive research. CanniOasis collaborates with A*STAR, a groundbreaking research institution that has achieved a remarkable milestone—the creation of the world's first mid-brain organoid model.
Unparalleled Innovations
in Neurology.
Our strategic advantage increases the barriers
of entry putting us miles ahead.
Manufacturing
Advanced purification techniques extract minor cannabinoids for pharmaceutical-grade excellence in cultivation.
- Use proprietary processes to create specific drug molecules through MiRNA screening.
- Balance precision therapy with the beneficial entourage effect of cannabinoids.
- Utilize drug delivery technologies for improved administration routes (oral, inhalation, etc.).
Clinical Trials
Know-how in creating clinical protocol that will be accepted by FDA.
- Strong support and development of its clinical trial protocols using its brain organoid models
- Fully functional laboratory in Singapore including state-of-the-art clinical trial technology
Regulatory Process
Stringent requirement for regulatory product approval.
- Wellness and medical cannabis have fewer regulatory requirements where claims of health benefits are not permitted
- Pharmaceutical cannabinoid-based drugs has high barrier of entry in regulatory that the team is capable of navigating